Insider Trading Activity Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) – Insider Sold 10,000 shares of Stock

ME Staff
-
0

Insider Trading Activity For Portola Pharmaceuticals, Inc. (NASDAQ:PTLA)

John T. Curnutte , Insider of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) reportedly Sold 10,000 shares of the company’s stock at an average price of 65 for a total transaction amount of $650,000.00 SEC Form

Insider Trading History For Portola Pharmaceuticals, Inc. (NASDAQ:PTLA)

  • On 5/28/2013 (Mauritius) Pte Ltd Maxwell, Major Shareholder, bought 700,000 with an average share price of $14.50 per share and the total transaction amounting to $10,150,000.00.View SEC Filing
  • On 10/22/2013 Charles J Homcy, Director, sold 95,962 with an average share price of $23.75 per share and the total transaction amounting to $2,279,097.50.View SEC Filing
  • On 3/25/2014 Mardi Dier, CFO, sold 5,000 with an average share price of $25.69 per share and the total transaction amounting to $128,450.00.View SEC Filing
  • On 4/25/2014 Mardi Dier, CFO, sold 5,000 with an average share price of $24.14 per share and the total transaction amounting to $120,700.00.View SEC Filing
  • On 5/16/2014 Jean Jacques Bienaime, Director, sold 1,000 with an average share price of $22.03 per share and the total transaction amounting to $22,030.00.View SEC Filing
  • On 5/21/2014 William Lis, CEO, sold 10,000 with an average share price of $19.87 per share and the total transaction amounting to $198,700.00.View SEC Filing
  • On 5/27/2014 William Lis, CEO, sold 30,000 with an average share price of $20.83 per share and the total transaction amounting to $624,900.00.View SEC Filing

    • Analyst Ratings For Portola Pharmaceuticals, Inc. (NASDAQ:PTLA)
    These are 2 Hold Ratings, 6 Buy Ratings .
    The current consensus rating for Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) is Buy (Score: 2.75) with a consensus target price of $61.50 , a potential (5.80% downside)

    Analyst Ratings History For Portola Pharmaceuticals, Inc. (NASDAQ:PTLA)

    • On 1/11/2017 Goldman Sachs Group, Inc. (The) Reiterated Rating Neutral with a price target of $22.00 to $27.00
    • On 2/24/2017 CIBC Upgraded rating Market Perform to Outperform
    • On 6/26/2017 Citigroup Inc. Boost Price Target of rating Buy with a price target of $51.00 to $78.00
    • On 6/26/2017 William Blair Reiterated Rating Outperform
    • On 6/26/2017 Cowen and Company Boost Price Target of rating Outperform with a price target of $45.00 to $70.00
    • On 6/26/2017 Oppenheimer Holdings, Inc. Boost Price Target of rating Outperform with a price target of $46.00 to $66.00
    • On 6/26/2017 Morgan Stanley Boost Price Target of rating Overweight with a price target of $50.00 to $70.00

    Recent Trading Activity for Portola Pharmaceuticals, Inc. (NASDAQ:PTLA)
    Shares of Portola Pharmaceuticals, Inc. closed the previous trading session at 65.29 up +0.31 0.48% with 857,141 shares trading hands.